This article is more than 5 years old. Information may no longer be current.

Most conjunctival tumors treated with MMC remained in remission at 2 years, study found

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

After treatment with topical mitomycin-C, most conjunctival tumors disappeared and did not recur for a mean period of 2 years, a small prospective study found.

Altan A. Ozcan, MD, and colleagues at Çukurova University in Adana, Turkey, evaluated use of the antimetabolite in nine eyes of nine patients with conjunctival tumors. In all cases, mitomycin-C (MMC) was applied in a 0.04% concentration four times daily for 1 week followed by 1 week without treatment; patients received one to six treatment courses.

At 24.6 months mean follow-up, tumors had completely disappeared without recurrence in seven patients. One patient did not experience tumor regression, and another had to cease treatment because of an adverse effect from the MMC.

Larger studies with longer follow-up are needed to determine the duration of tumor control, the authors noted. The study is published in the January issue of Ophthalmologica.